A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

Phase 1 Completed 36 enrolled SNIPR Biome Aps. Biomedical Advanced Research and Development Authority · collab Wellcome Trust · collab

RandomizedSequentialQuadruple-blindOther

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.

Timeline

Start: 2022-03-24
Primary completion: 2022-11-30
Completion: 2023-05-01

Publications

Petersen AO, Damholt B, Grove M, Hink J, Marotte-Hurbon T, Soderqvist J, Troy A, Zdravkovic M, Bayer L, Brunner K, Bryde T, Clube J, Gencay YE, Gram A, Haaber JK, Hallstrom B, Jasinskyte D, Pascal R, Petersen M, Semsey S, Torio AS, Turcu IC, Smrekar F, Taur Y, Satlin MJ, Sommer MOA, van der Helm E, Grondahl C. Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study. Lancet Microbe. 2026 Apr;7(4):101257. doi: 10.1016/j.lanmic.2025.101257. Epub 2026 Mar 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	SNIPR001	CRISPR / gene editing	1e+08 unknown	Oral
Comparator	SNIPR001	CRISPR / gene editing	1e+10 unknown	Oral
Comparator	SNIPR001	CRISPR / gene editing	1e+12 unknown	Oral

A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

Summary

Timeline

Publications

Drugs

Indications